ClinicalTrials.gg
RecruitingNCT07207486RF-2021-123742Updated Nov 5, 2026

In-depth Analysis of Cholesterol Metabolism and Related Biomarkers in the Pathogenesis and Progression of the Disease in Neurodegenerative Dementias

An observational study in Dementias and Neurodegenerative Dementia, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 2 sites in Italy. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Nov 5, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 92 studies in Dementia with a site in Italy — 37 open to participants now, 44 under way, 7 of them phase 3. Dementia · Italy.

Planned enrollment
24th of 26
80 · median 283
Started
2023
with 11 others
Observational
26 of 92
13 open now
Primary completion
2027-04
later than 26 of 43 live
Registered
80th of 92
by date

Among the 92 studies in Dementia with a site in Italy, this one is the 24th largest by planned enrollment of the 26 observational ones that give a count, is one of 12 that started in 2023, is one of 26 observational ones, reaches primary completion later than 26 of the 43 other live ones, and was the 80th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

37 of the 92 studies in Dementia with a site in Italy are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Dementia with a site in Italy, or all of them as a file.
02

Study summary

The aim of the study is to evaluate the role of cholesterol in the pathogenesis of neurodegenerative dementias. Hypercholesterolemia is a known risk factor for Alzheimer disease (AD), and oxysterols, the principal cholesterol metabolites, are involved in neuroinflammation, amyloid aggregation, and tau accumulation.

Oxysterols will be measured in different biological samples (post-mortem brain tissue, CSF, and plasma) from patients with different neurodegenerative dementias, including AD, frontotemporal dementia (FTD), and primary tauopathies. This approach will allow determination of whether their modifications correlate primarily with Aß deposition, tauopathy, or neuronal loss, with the goal of identifying correlations with disease severity and progression.

Since preliminary results suggest that the levels of most oxysterols in the brain significantly increase in parallel with the levels of the enzyme PCSK9, the investigators will explore the role of cholesterol metabolism and PCSK9 in AD and other dementias to evaluate whether cholesterol dysregulation represents a common alteration across these neurodegenerative disorders or is specific to AD

Read the detailed description

The project is a monocentric retrospective and prospective low-intervention clinical study. All samples collected will be sent for analysis to the Laboratory of General Pathology and Pathophysiology, Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy.

  1. Selection and characterization of post-mortem brains Twenty brains from patients with AD (ranging from Braak stage II to VI of neurofibrillary pathology severity), ten brains from patients with FTD/tauopathies, and six brains from FTD/TDP43 patients will be included in the study. These samples are already available for the project and have been neuropathologically characterized by Neurology 5 - Neuropathology Unit.
  2. Recruitment and follow-up of patients with neurodegenerative dementias

    Retrospective study Samples (CSF and plasma) previously collected from patients at Neurology 5 - Neuropathology Unit over the years will be used. The study will include 40 AD patients, 40 FTD patients, and 20 age-matched non-demented controls. Clinical and MRI data will be retrospectively collected, as well as levels of markers of neurodegeneration (tau, Abeta42, and phospho-tau) in CSF.

    Longitudinal study During the first 18 months of the project, 30 AD patients, 20 FTD patients, and 10 patients with primary tauopathies (PSP/CBD) will be recruited. A group of 20 age-matched healthy subjects will serve as controls. All patients and controls will undergo a comprehensive neurologic assessment, a neuropsychological evaluation, and a brain MRI with a standard protocol at baseline (T0) and after 1 year (T1). CSF collection will be performed at baseline in patients. DNA and plasma will be collected from controls and patients at baseline and follow-up. Measurements of BMI, total cholesterol, LDL and HDL cholesterol, and triglycerides will be performed at baseline and follow-up in all subjects. ApoE genotype will be analyzed for all subjects to determine E2, E3, and E4 polymorphisms. MRI will be performed on a 3T scanner, including volumetric T1, FLAIR, T2, DWI, and DTI sequences at baseline and follow-up.

  3. Study of the role of the enzyme PCSK9 in the brain (performed by University of Turin) SK-N-BE cells and mouse-derived primary cortical neurons and astrocytes will be treated with PCSK9 or with an oxysterol mixture obtained from brain dosages.
03

Conditions studied

  • Dementias
  • Neurodegenerative Dementia

Browse trials for

Keywords

  • Cholesterol metabolism
  • Neurodegenerative dementias
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

We will use samples (CSF and plasma) already collected from patients from Unit 1 over years. We will include 40 AD, 40 FTD and 20 age-matched non demented controls. Clinical and MRI data will be retrospectively collected as well as the levels of markers of neurodegeneration (tau, Abeta42 and phospho-tau) on CSF.

Longitudinal study We will recruit 30 AD patients, 20 FTD patients and 10 patients with primary tauopathies (PSP/CBD) from out and inpatients of Neurology 5-Neuropathology Unit. A group of 20 age-matched subjects without neurological and/or psychiatric diseases will be enrolled as controls. The duration of enrolment will be 18 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-85
  • Diagnosis based on the current diagnostic criteria for AD (McKhann et al., 2011), FTD (Gorno-Tempini et al., 2011; Rascovsky et al., 2011), PSP and CBD (Amstrong et al., 2013; Höglinger et al., 2017)
  • MMSE > 10.

Exclusion criteria

Exclusion Criteria:

  • Other neurological or psychiatric disorders Severe chronic metabolic diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • AD

    Patient with Alzheimer's disease

  • FTD

    Patient wirh Frontotemporal dementia

  • PSP/CBD

    Patient with tauopathy

  • CN

    Controll subjects

06

What researchers measure

Primary outcomes

  1. Characterize differences in cholesterol precursors

    To identify and characterize differences in cholesterol precursors and metabolites between patients with neurodegenerative dementias vs controls and between patients with different types of neurodegenerative dementia.

    Time frame: 12 months

Secondary outcomes

  1. different brain areas

    To identify and characterize different levels of cholesterol precursors and metabolites as well as lipidomics and metabolomics changes in different brain areas of the same patients categorized as involved or spared by the different types of pathological changes.

    Time frame: 12 months

  2. cerebral oxysterol changes in AD

    To find out whether cerebral oxysterol changes in AD (see preliminary results) involve globally the brain suggesting a general derangement of cerebral cholesterol metabolism or selectively brain areas involved by specific primary (Abeta deposition, tauopathy) or secondary (astrogliosis, microglial activation, neuroinflammation) alterations

    Time frame: 12 months

  3. different cholesterol precursors in neurodegenerative diseases examined in CSF and plasma

    To identify different levels of cholesterol precursors and metabolites as well as lipidomics and metabolomics changes at different stages of the different neurodegenerative diseases examined in CSF and plasma.

    Time frame: 12 months

  4. cortical atrophy

    To ascertain whether correlations exist between cholesterol precursors and metabolites abnormalities, severity of the disease, cortical atrophy, glial and microglial reactive changes and neuroinflammation in neurodegenerative dementias.

    Time frame: 12 months

  5. PCSK9

    To verify whether changes in the levels of PCSK9 and other cholesterol metabolism-related proteins are present in patients with the neurodegenerative dementias (brain tissue, CSF, and plasma).

    Time frame: 12 months

  6. PCSK9 in neurons

    Levels of inflammatory markers and neurodegeneration-related proteins in neurons and astrocytes after treatment with PCSK9 in vitro.

    Time frame: 12 months

  7. potential neurotoxic action of PCSK9

    Efficacy of the new nanoparticle (NPs) formulation carrying anti-PCSK9 antibody in reducing PCSK9-induced neurotoxicity in neuronal and astrocyte cultures in vitro.

    Time frame: 12 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Apr 2027, 46 months after the start.

Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 46 months is below that.

Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 6, 2025
StartActual
Jun 5, 2023
Primary completionEst.
Apr 29, 2027
CompletionEst.
Apr 29, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Collaborators added: San Luigi Gonzaga Hospital; collaborators removed: Ospedale San Luigi Gonzaga, Orbassano
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Sponsor Collaborators added: San Luigi Gonzaga Hospital; collaborators removed: Ospedale San Luigi Gonzaga, Orbassano
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07207486
Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators
Università di Torino, Torino, San Luigi Gonzaga Hospital
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Jun 5, 2023
Primary completion
Apr 29, 2027 (estimated)
Completion
Apr 29, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Paola Caroppo, MD
Contact
paola.caroppo@istituto-besta.it
02.2394.2260 ext. 2260
Aurora Romeo, SC
Contact
aurora.romeo@istituto-besta.it
02.2394.2260

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion